Press "Enter" to skip to content

One Billion worth Merck Covid-19 Pill to be Bought

On Tuesday, Merck & Co Inc and partner Ridgeback Biotherapeutics said that the US government would purchase another $1 billion worth of COVID-19 pills. The government agreed to buy 1.7 million molnupiravir courses for $1.2 billion in June and is now considering buying 1.4 million more. This raises the overall number of secured classes to 3.1 million, with a total value of $2.2 billion. According to Merck, as part of the arrangement, the government can purchase an additional 2 million courses.

Data released last month revealed that if taken early in the illness, the medicine could cut the risk of dying or being hospitalized among people most at risk of developing severe COVID-19 by half. Frank Clyburn, president of Merck human health business, said, “Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end.”

On Friday, President Joe Biden announced that the US had also acquired millions of doses of Pfizer Inc’s competing antiviral medication, which has been demonstrated to reduce the risk of hospitalization or death in adults at risk of severe disease by 89 percent.

A senior US health official confirmed a New York Times article on Tuesday that the Pfizer negotiations were for a contract identical to the one with Merck – 1.7 million courses of the medication upfront with an option for 3.3 million, according to a senior US health official. ON FRIDAY, Pfizer CEO Alfred Bourla said that the company expects to market its medicine for around the same price as Merck in high-income nations, around $700 for a course of treatment.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *